Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer.
If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.